The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2.
about
Sphingolipids: a potential molecular approach to treat allergic inflammationFTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacologyFTY720 inhibits ceramide synthases and up-regulates dihydrosphingosine 1-phosphate formation in human lung endothelial cellsRoles of bioactive sphingolipids in cancer biology and therapeuticsRole of ABCC1 in export of sphingosine-1-phosphate from mast cellsThe immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptorsThe emerging role of FTY720 (Fingolimod) in cancer treatmentSphingosine 1-phosphate receptor modulators in multiple sclerosisSphingosine-1-phosphate in chronic intestinal inflammation and cancerLysophospholipid receptors in drug discovery.Biological characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a selective sphingosine kinase-2 inhibitor and anticancer agentPreclinical Metabolism, Pharmacokinetics and In Vivo Analysis of New Blood-Brain-Barrier Penetrant Fingolimod Analogues: FTY720-C2 and FTY720-MitoxyHypoxic preconditioning induces stroke tolerance in mice via a cascading HIF, sphingosine kinase, and CCL2 signaling pathwaySphingosine kinase 1 and sphingosine 1-phosphate receptor 3 are functionally upregulated on astrocytes under pro-inflammatory conditionsStructure-activity relationship studies and in vivo activity of guanidine-based sphingosine kinase inhibitors: discovery of SphK1- and SphK2-selective inhibitors.Engineering in vivo gradients of sphingosine-1-phosphate receptor ligands for localized microvascular remodeling and inflammatory cell positioningSphingosine 1-phosphate enhances the excitability of rat sensory neurons through activation of sphingosine 1-phosphate receptors 1 and/or 3Sphingosine kinase type 2 inhibition elevates circulating sphingosine 1-phosphate.Sphingosine 1-phosphate chemical biologySynthesis and biological evaluation of sphingosine kinase substrates as sphingosine-1-phosphate receptor prodrugs.Targeting sphingosine 1 phosphate receptor type 1 receptors in acute kidney injury.B lymphocytes exit lymph nodes through cortical lymphatic sinusoids by a mechanism independent of sphingosine-1-phosphate-mediated chemotaxis.Mammalian sphingosine kinase (SphK) isoenzymes and isoform expression: challenges for SphK as an oncotarget.Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.Lipid isolated from a Leishmania donovani strain reduces Escherichia coli induced sepsis in mice through inhibition of inflammatory responsesThe sphingosine 1-phosphate transporter, SPNS2, functions as a transporter of the phosphorylated form of the immunomodulating agent FTY720.Extracellular and intracellular actions of sphingosine-1-phosphateVessel-specific role of sphingosine kinase 1 in the vasoconstriction of isolated basilar arteries.Further characterization of mammalian ceramide kinase: substrate delivery and (stereo)specificity, tissue distribution, and subcellular localization studies.FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.Cardiovascular effects of fingolimod: A review article.Fingolimod for relapsing multiple sclerosis: an update.Purification and identification of activating enzymes of CS-0777, a selective sphingosine 1-phosphate receptor 1 modulator, in erythrocytesSphingosine-1-phosphate promotes extravillous trophoblast cell invasion by activating MEK/ERK/MMP-2 signaling pathways via S1P/S1PR1 axis activationImmunomodulator FTY720 induces myofibroblast differentiation via the lysophospholipid receptor S1P3 and Smad3 signaling.An overview of pharmacological approaches for management and repair of spinal cord injuries.Differential regulation of autophagy and cell viability by ceramide species.FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphomaThe sphingosine and diacylglycerol kinase superfamily of signaling kinases: localization as a key to signaling function.Increased survival and reduced renal injury in MRL/lpr mice treated with a novel sphingosine-1-phosphate receptor agonist.
P2860
Q21296721-757747C5-21F6-4FDA-BA38-B7D3DFD259D7Q24643383-96B4F0FA-7544-425D-89FA-ECFEC82CEBD4Q24650419-F550A998-966E-4D81-93A4-794CF49AAFC1Q24657499-AB5629E0-5148-484A-BDFF-9D6C9517F286Q24671687-1E4CD725-839A-4FFB-8835-282396AB83C3Q24681206-4FB903FF-9D21-4E36-972D-A3B1EDD6D5C4Q26748927-CAE643BF-2667-4C3D-A8EA-17193F562672Q26799440-54972507-EA51-44F6-9D2F-48AA2F0D02FFQ26852824-9775EB60-7C1D-4150-8C93-89335F1D6813Q27692680-E3270BFF-0126-422C-A149-AABA825900E8Q28486289-DBCAD9F2-D601-46C4-924F-4C8A81A3639BQ28553993-AAE29C5D-6607-4811-B1AB-2C16CE6E5A59Q28593650-4870ADA2-3E61-4173-930C-507ED764ACBAQ28741063-2F2054EF-0B33-41DE-A68D-86FF17E79D7CQ30360636-F862802B-3D1E-4259-8882-4E0B93F1FED6Q30370009-07808B1A-B34E-488F-BF76-5CB19AE1981DQ30405763-D8AC5034-3A7C-48CB-8797-87092C2ACD11Q30416881-B012C275-DD4F-46DB-AEB8-A5028F7B23FBQ30425603-075B6A0B-30EE-4477-A585-36E28380BF21Q30435057-36E72B8B-2E5E-4E70-804D-B7EF892D9AF5Q30439643-1B8D42E0-E54F-4AB9-8596-B62D7AF74F5DQ30490219-9E76AA91-1FCA-416E-A677-5E5224A38928Q33829692-F37DFEC1-75D5-4846-8261-E1F62F571CD5Q33881977-3B0FC28A-2B1C-45AD-BE3F-375BE63F143BQ33998530-A6180CBF-8060-4EFF-B371-9E29D3AA4C90Q34150336-F936DE07-EA65-48DA-9773-B9692F5DA027Q34183703-BD07744B-195D-43A8-8880-36317CFA49C1Q34283351-D6CB0E41-29B5-4D5A-8B06-44D564561CB1Q34465333-9BE67916-078C-4101-A29C-8B7A2E67E1ADQ34490581-3A80FAAF-2CD1-482B-8B13-EC8653511976Q34558943-168F82EC-3DE4-449E-9DC3-4B7FC728589BQ34618474-A138482A-5FF7-4D90-B10F-1803BA4D32E9Q35107430-234D3EC5-E999-46EC-8436-C9449EC686DBQ35238341-7FF22920-1510-49EE-BC7A-D6822683066EQ35570447-D2E29FEE-42ED-4624-A93D-391334FD6671Q36092501-430A7140-C38E-461E-8A50-A94F94C4556CQ36214943-FDC23606-6B05-46C9-BE9B-5BA4CA0C7598Q36384629-16C021C6-9FD2-4191-BF77-6267210EC505Q36415172-777041DC-9396-4B34-A455-7E163C57681AQ36461786-2D17A155-15EA-4407-BC30-CA2874384ED0
P2860
The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2.
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2.
@ast
The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2.
@en
The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2.
@nl
type
label
The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2.
@ast
The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2.
@en
The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2.
@nl
prefLabel
The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2.
@ast
The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2.
@en
The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2.
@nl
P2093
P2860
P1433
P1476
The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2.
@en
P2093
Shawn G Payne
Sheldon Milstien
Steven W Paugh
Suzanne E Barbour
P2860
P304
P356
10.1016/S0014-5793(03)01168-2
P407
P577
2003-11-01T00:00:00Z